Chardan Capital Boosts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $29.00

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its target price upped by analysts at Chardan Capital from $27.00 to $29.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price objective would indicate a potential upside of 84.01% from the stock’s previous close.

EYPT has been the topic of several other research reports. Royal Bank Of Canada lifted their target price on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. Finally, TD Cowen upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $31.50.

Eyepoint Pharmaceuticals Stock Performance

EYPT opened at $15.76 on Wednesday. Eyepoint Pharmaceuticals has a fifty-two week low of $3.91 and a fifty-two week high of $19.11. The firm’s fifty day moving average is $15.71 and its 200 day moving average is $14.32. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -4.99 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 93.46% and a negative net margin of 739.39%.The business had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.01 million. On average, equities research analysts predict that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Insider Activity at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 42,544 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several institutional investors have recently bought and sold shares of EYPT. Suvretta Capital Management LLC grew its stake in shares of Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock worth $143,012,000 after buying an additional 1,634,970 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Eyepoint Pharmaceuticals by 9.7% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock valued at $63,988,000 after acquiring an additional 600,000 shares during the last quarter. Federated Hermes Inc. grew its position in Eyepoint Pharmaceuticals by 36.3% in the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock worth $109,938,000 after acquiring an additional 1,601,101 shares in the last quarter. Franklin Resources Inc. increased its stake in Eyepoint Pharmaceuticals by 19.3% during the fourth quarter. Franklin Resources Inc. now owns 4,976,915 shares of the company’s stock worth $90,928,000 after acquiring an additional 805,031 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Eyepoint Pharmaceuticals by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company’s stock valued at $88,100,000 after purchasing an additional 1,027,623 shares during the period. Institutional investors own 99.41% of the company’s stock.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Analysts raised targets and reiterated buys—HC Wainwright boosted its price target to $30 (buy) and Chardan raised its target to $29 (buy), both implying large upside versus the current share price. Benzinga TickerReport
• Positive Sentiment: Pipeline and commercial-readiness updates: company says both pivotal Phase 3 trials for DURAVYU in wet AMD are on track for mid‑2026 readouts, patients are being dosed in DME trials, a chief commercial officer was appointed, and EyePoint reported >$300M in cash and investments (runway into Q4 2027)—all support a credible launch pathway if trials succeed. Press Release
• Neutral Sentiment: Company set a clear mid‑2026 topline target for DURAVYU readouts, which clarifies timing risk but keeps outcome risk high until data are reported. Article
• Neutral Sentiment: Reported short-interest data for March appear anomalous (showing 0 shares and NaN changes), so there’s no clear short‑squeeze signal from the available short‑interest report; treat that item as unreliable until clarified.
• Negative Sentiment: Quarterly results disappointed on EPS and revenue—Q4 EPS was a ($0.81) loss versus consensus ($0.78) and reported revenue was $0.62M (below some analyst expectations). The company also reported wide negative margins and negative ROE, highlighting near‑term profitability challenges that can pressure the stock. Earnings Transcript Press Release PDF
• Negative Sentiment: Investor caution: recent commentary (Seeking Alpha) warns that a pre‑readout runup may be masking commercial risks and execution hurdles—this kind of narrative can prompt profit‑taking ahead of pivotal data. Seeking Alpha

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.